prikaz prve stranice dokumenta A summary of current NKG2D-based CAR clinical trials
  Download
PDF 368.36 KB
Scientific paper - Review paper
A summary of current NKG2D-based CAR clinical trials
Immunotherapy Advances, 1 (2021), 1; 1-8. https://doi.org/10.1093/immadv/ltab018
Curio, Sophie; Jonsson, Gustav; Marinović, Sonja

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Curio, S., Jonsson, G. & Marinović, S. (2021). A summary of current NKG2D-based CAR clinical trials. Immunotherapy Advances, 1. (1), 1-8. doi: 10.1093/immadv/ltab018

Curio, Sophie, et al. "A summary of current NKG2D-based CAR clinical trials." Immunotherapy Advances, vol. 1, no. 1, 2021, pp. 1-8. https://doi.org/10.1093/immadv/ltab018

Curio, Sophie, Gustav Jonsson and Sonja Marinović. "A summary of current NKG2D-based CAR clinical trials." Immunotherapy Advances 1, no. 1 (2021): 1-8. https://doi.org/10.1093/immadv/ltab018

Curio, S., Jonsson, G. and Marinović, S. (2021) 'A summary of current NKG2D-based CAR clinical trials', Immunotherapy Advances, 1(1), pp. 1-8. doi: 10.1093/immadv/ltab018

Curio S, Jonsson G, Marinović S. A summary of current NKG2D-based CAR clinical trials. Immunotherapy Advances [Internet]. 2021 January 01 [cited 2024 July 14];1(1):1-8. doi: 10.1093/immadv/ltab018

S. Curio, G. Jonsson and S. Marinović, "A summary of current NKG2D-based CAR clinical trials", Immunotherapy Advances, vol. 1, no. 1, pp. 1-8, January 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:286089. [Accessed: 14 July 2024]

Metadata
Title (english)A summary of current NKG2D-based CAR clinical trials
AuthorSophie Curio
AuthorGustav Jonsson
AuthorSonja Marinović
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Histology and Embryology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Abstract (english)
Summary Cancer immunotherapies have significantly improved patient survival and treatment options in recent years. Nonetheless, the success of immunotherapy is limited to certain cancer types and specific subgroups of patients, making the development of new therapeutic approaches a topic of ongoing research. Chimeric antigen receptor (CAR) cells are engineered immune cells that are programmed to specifically eliminate cancer cells. Ideally, a CAR recognizes antigens that are restricted to tumor cells to avoid off-target effects. NKG2D is an activating immunoreceptor and an important player in anti-tumor immunity due to its ability to recognize tumor cells and initiate an anti-tumor immune response. Ligands for NKG2D are expressed on malignant or stressed cells and typically absent from healthy tissue, making it a promising CAR candidate. Here, we provide a summary of past and ongoing NKG2D-based CAR clinical trials and comment on potential pitfalls.
Keywords (english)
Languageenglish
Publication typeScientific paper - Review paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleImmunotherapy Advances
Numberingvol. 1, no. 1, pp. 1-8
e-ISSN2732-4303
DOIhttps://doi.org/10.1093/immadv/ltab018
URN:NBNurn:nbn:hr:184:286089
Publication2021-01-01
Document URLhttps://academic.oup.com/immunotherapyadv/article/doi/10.1093/immadv/ltab018/6350805
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2022-09-26 12:26:07